IDiyas

For the Inventor, By the Inventor

Belmont, CA, United States of America

Deryk T Loo

USPTO Granted Patents = 17 

 

 

Average Co-Inventor Count = 3.6

ph-index = 4

Forward Citations = 75(Granted Patents)


Company Filing History:

goldMedal13 out of 130 
 
Macrogenics, Inc.
 patents
silverMedal2 out of 4 
 
Macrogenics West, Inc.
 patents
bronzeMedal1 out of 18 
 
Raven Biotechnologies, Inc.
 patents
4. 1 out of 832,680 
Other
 patents

Years Active: 2010-2023

Loading Chart...
Loading Chart...
Loading Chart...
17 patents (USPTO):Explore Patents
1. 11591400 - B7-H3 directed antibody drug conjugates (2023-02-28),
2. 11242402 - ADAM9-binding molecules, and methods of use thereof (2022-02-08),
3. 10961311 - B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof (2021-03-30),
4. 10730945 - Antibodies reactive with B7-H3 and users thereof (2020-08-04),
5. 10683364 - Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof (2020-06-16),
6. 9896508 - Antibodies reactive with B7-H3 and uses thereof (2018-02-20),
7. 9714296 - Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof (2017-07-25),
8. 9714295 - Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof (2017-07-25),
9. 9441049 - Antibodies reactive with B7-H3 and uses thereof (2016-09-13),
10. 9150656 - Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof (2015-10-06),
11. 8802091 - Antibodies reactive with B7-H3 and uses thereof (2014-08-12),
12. 8440197 - KID3 and KID3 antibodies that bind thereto (2013-05-14),
13. 8361475 - ADAM-9 modulators (2013-01-29),
14. 8313916 - KID31 and antibodies that bind thereto (2012-11-20),
15. 7790855 - KID3 and KID3 antibodies that bind thereto (2010-09-07),

Title: Spotlight on Inventor Deryk T Loo: Pioneering Advances in Cancer Treatment

Introduction:

Deryk T Loo, a prolific inventor based in Belmont, CA, is making significant strides in the field of cancer treatment with his groundbreaking patented innovations.

Latest Patents:

Loo's latest patents showcase his ingenuity in developing B7-H3 directed antibody drug conjugates, which are novel molecules capable of targeting B7-H3 in both human and non-human subjects. These molecules have been designed to exhibit reduced immunogenicity, offering promise in the treatment of various diseases, particularly cancer. Additionally, Loo's patents include ADAM9-binding molecules that show high affinity binding to ADAM9, opening new possibilities in cancer therapy and beyond.

Career Highlights:

With an impressive portfolio of 17 patents, Loo has established himself as a key figure in the biopharmaceutical innovation landscape. His work at esteemed companies like Macrogenics, Inc. and Macrogenics West, Inc. has been instrumental in advancing cutting-edge research and development in the healthcare sector.

Collaborations:

Throughout his career, Loo has collaborated closely with top talents in the industry, including notable coworkers such as Leslie Sydnor Johnson and Ling Ling Huang. These collaborations have been essential in driving forward the translation of innovative ideas into impactful solutions for patient care.

Conclusion:

Inventor Deryk T Loo's dedication to pushing the boundaries of scientific discovery and his remarkable contributions to the field of cancer therapeutics highlight his unwavering commitment to improving health outcomes. His pioneering work serves as a beacon of hope for the future of precision medicine and targeted treatments in oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…